ClinicalTrials.gg

Program

9MW1911

Also written as “9MW1911 Injection”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by Mabwell (Shanghai) Bioscience.

Furthest: phase 2, since Dec 4, 20233 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mabwell (Shanghai) Bioscience32 open or runningphase 2since Dec 4, 2023Dec 12, 2021Dec 2027phase 2 · NCT07292714

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2021First study: phase 1 study in AsthmaFirst studyNCT05170243 · 28 enrolled · China
  2. Dec 4, 2023Phase 2 study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT06175351 · 80 enrolled · China
  3. Dec 2, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07292714 · 360 planned · China

Ahead

  1. Dec 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07292714

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07292714Pulmonary Disease, Chronic Obstructive · China2RecruitingDec 2027360
NCT06175351Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) · China2Active, not recruitingSep 30, 202580
NCT05170243Asthma · China1CompletedJul 3, 202228

How it is read

Names in the registry

  • “9MW1911”, 2 entries
  • “9MW1911 Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.